Expression microarray analysis identifies novel epithelial-derived protein markers in eosinophilic esophagitis

Andres Matoso, Vincent A. Mukkada, Shaolei Lu, Renee Monahan, Kelly Cleveland, Lelia Noble, Shamlal Mangray, Murray B. Resnick

Research output: Contribution to journalArticle

Abstract

Gene expression studies in eosinophilic esophagitis support an immune-mediated etiology associated with differential regulation of inflammatory and epithelial-derived genes. We aimed to further characterize epithelial gene expression alterations in eosinophilic esophagitis and to explore the use of immunohistochemistry to identify these alterations. Esophageal biopsies from pediatric patients with eosinophilic esophagitis before and after therapy with topical steroids (N=7) were screened by gene expression microarray and results were validated by RT-PCR. A larger group of eosinophilic esophagitis patients (N=42) was then used to evaluate protein expression by immunohistochemistry compared with reflux patients (N=15) and normal controls (N=17). Microarray and RT-PCR studies identified overexpression of ALOX15 and tumor necrosis factor alpha-induced factor 6 (TNFAIP6) and underexpression of filaggrin (FLG), SLURP1 and cysteine-rich secretory protein 3 (CRISP3) in eosinophilic esophagitis. Immunohistochemistry for ALOX15 was positive in 95% of eosinophilic esophagitis and negative in all controls, all eosinophilic esophagitis after therapy and all reflux biopsies (P<0.001). TNFAIP6 was positive in 88% of eosinophilic esophagitis samples versus 47% of controls, 29% of eosinophilic esophagitis after therapy and 40% of reflux samples (P=0.002). Overexpression of both ALOX15 and TNFAIP6 directly correlated with the degree of eosinophilic infiltration. FLG was positive in 88% of controls and 100% of reflux biopsies, but negative in all eosinophilic esophagitis samples, and its expression was regained in 86% of eosinophilic esophagitis after therapy patients (P<0.001). SLURP1 expression was positive in all controls and reflux samples, but only positive in 5% of eosinophilic esophagitis and was re-expressed to 100% positivity in eosinophilic esophagitis after therapy patients (P<0.001). The majority of controls (89%) and reflux biopsies (100%) were positive for CRISP3 while eosinophilic esophagitis before therapy were positive in 14% of samples (P<0.001) with partial recovery after treatment (43%, P=0.105). This study identified five epithelial-derived markers differentially expressed in eosinophilic esophagitis easily detectable by immunohistochemistry with potential diagnostic utility.

Original languageEnglish (US)
Pages (from-to)665-676
Number of pages12
JournalModern Pathology
Volume26
Issue number5
DOIs
StatePublished - May 1 2013
Externally publishedYes

Fingerprint

Eosinophilic Esophagitis
Microarray Analysis
Proteins
Immunohistochemistry
Biopsy
Gene Expression
Therapeutics
Cysteine
Polymerase Chain Reaction

Keywords

  • ALOX15
  • CRISP3
  • eosinophilic esophagitis
  • FLG
  • immunohistochemistry
  • SLURP1
  • TNFAIP6

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Expression microarray analysis identifies novel epithelial-derived protein markers in eosinophilic esophagitis. / Matoso, Andres; Mukkada, Vincent A.; Lu, Shaolei; Monahan, Renee; Cleveland, Kelly; Noble, Lelia; Mangray, Shamlal; Resnick, Murray B.

In: Modern Pathology, Vol. 26, No. 5, 01.05.2013, p. 665-676.

Research output: Contribution to journalArticle

Matoso, A, Mukkada, VA, Lu, S, Monahan, R, Cleveland, K, Noble, L, Mangray, S & Resnick, MB 2013, 'Expression microarray analysis identifies novel epithelial-derived protein markers in eosinophilic esophagitis', Modern Pathology, vol. 26, no. 5, pp. 665-676. https://doi.org/10.1038/modpathol.2013.41
Matoso, Andres ; Mukkada, Vincent A. ; Lu, Shaolei ; Monahan, Renee ; Cleveland, Kelly ; Noble, Lelia ; Mangray, Shamlal ; Resnick, Murray B. / Expression microarray analysis identifies novel epithelial-derived protein markers in eosinophilic esophagitis. In: Modern Pathology. 2013 ; Vol. 26, No. 5. pp. 665-676.
@article{b272523ddb3c49148f002fe26982b1a2,
title = "Expression microarray analysis identifies novel epithelial-derived protein markers in eosinophilic esophagitis",
abstract = "Gene expression studies in eosinophilic esophagitis support an immune-mediated etiology associated with differential regulation of inflammatory and epithelial-derived genes. We aimed to further characterize epithelial gene expression alterations in eosinophilic esophagitis and to explore the use of immunohistochemistry to identify these alterations. Esophageal biopsies from pediatric patients with eosinophilic esophagitis before and after therapy with topical steroids (N=7) were screened by gene expression microarray and results were validated by RT-PCR. A larger group of eosinophilic esophagitis patients (N=42) was then used to evaluate protein expression by immunohistochemistry compared with reflux patients (N=15) and normal controls (N=17). Microarray and RT-PCR studies identified overexpression of ALOX15 and tumor necrosis factor alpha-induced factor 6 (TNFAIP6) and underexpression of filaggrin (FLG), SLURP1 and cysteine-rich secretory protein 3 (CRISP3) in eosinophilic esophagitis. Immunohistochemistry for ALOX15 was positive in 95{\%} of eosinophilic esophagitis and negative in all controls, all eosinophilic esophagitis after therapy and all reflux biopsies (P<0.001). TNFAIP6 was positive in 88{\%} of eosinophilic esophagitis samples versus 47{\%} of controls, 29{\%} of eosinophilic esophagitis after therapy and 40{\%} of reflux samples (P=0.002). Overexpression of both ALOX15 and TNFAIP6 directly correlated with the degree of eosinophilic infiltration. FLG was positive in 88{\%} of controls and 100{\%} of reflux biopsies, but negative in all eosinophilic esophagitis samples, and its expression was regained in 86{\%} of eosinophilic esophagitis after therapy patients (P<0.001). SLURP1 expression was positive in all controls and reflux samples, but only positive in 5{\%} of eosinophilic esophagitis and was re-expressed to 100{\%} positivity in eosinophilic esophagitis after therapy patients (P<0.001). The majority of controls (89{\%}) and reflux biopsies (100{\%}) were positive for CRISP3 while eosinophilic esophagitis before therapy were positive in 14{\%} of samples (P<0.001) with partial recovery after treatment (43{\%}, P=0.105). This study identified five epithelial-derived markers differentially expressed in eosinophilic esophagitis easily detectable by immunohistochemistry with potential diagnostic utility.",
keywords = "ALOX15, CRISP3, eosinophilic esophagitis, FLG, immunohistochemistry, SLURP1, TNFAIP6",
author = "Andres Matoso and Mukkada, {Vincent A.} and Shaolei Lu and Renee Monahan and Kelly Cleveland and Lelia Noble and Shamlal Mangray and Resnick, {Murray B.}",
year = "2013",
month = "5",
day = "1",
doi = "10.1038/modpathol.2013.41",
language = "English (US)",
volume = "26",
pages = "665--676",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Expression microarray analysis identifies novel epithelial-derived protein markers in eosinophilic esophagitis

AU - Matoso, Andres

AU - Mukkada, Vincent A.

AU - Lu, Shaolei

AU - Monahan, Renee

AU - Cleveland, Kelly

AU - Noble, Lelia

AU - Mangray, Shamlal

AU - Resnick, Murray B.

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Gene expression studies in eosinophilic esophagitis support an immune-mediated etiology associated with differential regulation of inflammatory and epithelial-derived genes. We aimed to further characterize epithelial gene expression alterations in eosinophilic esophagitis and to explore the use of immunohistochemistry to identify these alterations. Esophageal biopsies from pediatric patients with eosinophilic esophagitis before and after therapy with topical steroids (N=7) were screened by gene expression microarray and results were validated by RT-PCR. A larger group of eosinophilic esophagitis patients (N=42) was then used to evaluate protein expression by immunohistochemistry compared with reflux patients (N=15) and normal controls (N=17). Microarray and RT-PCR studies identified overexpression of ALOX15 and tumor necrosis factor alpha-induced factor 6 (TNFAIP6) and underexpression of filaggrin (FLG), SLURP1 and cysteine-rich secretory protein 3 (CRISP3) in eosinophilic esophagitis. Immunohistochemistry for ALOX15 was positive in 95% of eosinophilic esophagitis and negative in all controls, all eosinophilic esophagitis after therapy and all reflux biopsies (P<0.001). TNFAIP6 was positive in 88% of eosinophilic esophagitis samples versus 47% of controls, 29% of eosinophilic esophagitis after therapy and 40% of reflux samples (P=0.002). Overexpression of both ALOX15 and TNFAIP6 directly correlated with the degree of eosinophilic infiltration. FLG was positive in 88% of controls and 100% of reflux biopsies, but negative in all eosinophilic esophagitis samples, and its expression was regained in 86% of eosinophilic esophagitis after therapy patients (P<0.001). SLURP1 expression was positive in all controls and reflux samples, but only positive in 5% of eosinophilic esophagitis and was re-expressed to 100% positivity in eosinophilic esophagitis after therapy patients (P<0.001). The majority of controls (89%) and reflux biopsies (100%) were positive for CRISP3 while eosinophilic esophagitis before therapy were positive in 14% of samples (P<0.001) with partial recovery after treatment (43%, P=0.105). This study identified five epithelial-derived markers differentially expressed in eosinophilic esophagitis easily detectable by immunohistochemistry with potential diagnostic utility.

AB - Gene expression studies in eosinophilic esophagitis support an immune-mediated etiology associated with differential regulation of inflammatory and epithelial-derived genes. We aimed to further characterize epithelial gene expression alterations in eosinophilic esophagitis and to explore the use of immunohistochemistry to identify these alterations. Esophageal biopsies from pediatric patients with eosinophilic esophagitis before and after therapy with topical steroids (N=7) were screened by gene expression microarray and results were validated by RT-PCR. A larger group of eosinophilic esophagitis patients (N=42) was then used to evaluate protein expression by immunohistochemistry compared with reflux patients (N=15) and normal controls (N=17). Microarray and RT-PCR studies identified overexpression of ALOX15 and tumor necrosis factor alpha-induced factor 6 (TNFAIP6) and underexpression of filaggrin (FLG), SLURP1 and cysteine-rich secretory protein 3 (CRISP3) in eosinophilic esophagitis. Immunohistochemistry for ALOX15 was positive in 95% of eosinophilic esophagitis and negative in all controls, all eosinophilic esophagitis after therapy and all reflux biopsies (P<0.001). TNFAIP6 was positive in 88% of eosinophilic esophagitis samples versus 47% of controls, 29% of eosinophilic esophagitis after therapy and 40% of reflux samples (P=0.002). Overexpression of both ALOX15 and TNFAIP6 directly correlated with the degree of eosinophilic infiltration. FLG was positive in 88% of controls and 100% of reflux biopsies, but negative in all eosinophilic esophagitis samples, and its expression was regained in 86% of eosinophilic esophagitis after therapy patients (P<0.001). SLURP1 expression was positive in all controls and reflux samples, but only positive in 5% of eosinophilic esophagitis and was re-expressed to 100% positivity in eosinophilic esophagitis after therapy patients (P<0.001). The majority of controls (89%) and reflux biopsies (100%) were positive for CRISP3 while eosinophilic esophagitis before therapy were positive in 14% of samples (P<0.001) with partial recovery after treatment (43%, P=0.105). This study identified five epithelial-derived markers differentially expressed in eosinophilic esophagitis easily detectable by immunohistochemistry with potential diagnostic utility.

KW - ALOX15

KW - CRISP3

KW - eosinophilic esophagitis

KW - FLG

KW - immunohistochemistry

KW - SLURP1

KW - TNFAIP6

UR - http://www.scopus.com/inward/record.url?scp=84877028770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877028770&partnerID=8YFLogxK

U2 - 10.1038/modpathol.2013.41

DO - 10.1038/modpathol.2013.41

M3 - Article

C2 - 23503644

AN - SCOPUS:84877028770

VL - 26

SP - 665

EP - 676

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 5

ER -